| Name | Title | Contact Details |
|---|---|---|
Sumita Ray |
General Counsel | Profile |
Orchard Therapeutics is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott Aldrich syndrome) and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline. The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele. Orchard is a publicly traded company (NASDAQ: ORTX) with offices in the UK and the US, including London, San Francisco and Boston.
Sonoma Biotherapeutics is inventing the future of living therapies for autoimmune disease — safe, effective treatments as unique as each individual patient. Regulatory T cell therapies that harness a patient`s own immune cells, powerful next generation gene editing techniques and advanced manufacturing and quality assurance processes. Sonoma`s mission is to create a best-in-class regulatory T cell therapy that delivers long-lasting, highly efficacious treatments leading to cures across a spectrum of autoimmune and degenerative diseases.
We are a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing therapies. By pioneering targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.
MBio Diagnostics is now LightDeck Diagnostics! LightDeck Diagnostics believes in a new approach to healthcare, where fast, accurate, simple, low-cost diagnostic tests will be run wherever and whenever they are needed, without compromise.
Active Motif is a fast-growing biotechnology company that is dedicated to developing new and innovative tools & techniques that help analyze nuclear function. Our employees are our biggest asset and our corporate policy is to treat them as such. This